In Olanzapine patent disputes, the Supreme Court ruled as we claimed. See, decision in Lilly Korea v. Hanmi and decision in Lilly Korea v. Myung-In (all in Korean). The Court did not recognize that generic companies are liable for the reduction of upper price limit of patented product, Zyprexa (Olanzapine) even when the reduction was …
Written submission on olanzapine patent was filed to the Korean Supreme Court, which was officially accepted by the Court on October 31, 2019. PDF documents of the submission are available at here and here (all in Korean). The submission was endorsed by five CSOs (Knowledge Commune, Commons Foundation, Center for Health and Social Change, Association …
Eli Lilly’s patent on olanzapine product (Zyprexa) invoked a number of disputes with generic companies across the world. The main challenge of the generic companies is the lack of novelty or inventiveness of the patent. Some jurisdictions found the patent valid, and others first decided in favor of generics (for instance, Germany and Korea). In …